Skip to main content Accessibility help
×
Home
  • Cited by 1
  • Print publication year: 2016
  • Online publication date: March 2016

Chapter 2 - Contraception in women with heart disease

from Section 1 - Pregnancy Counseling and Contraception
1.Nelson-Piercy, C. Cardiac disease. Saving Mothers’ Lives: Reviewing maternal deaths to make motherhood safer 2006–2008. The Eighth Report on Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 2011;118(Suppl 1):109–15.
2.World Health Organization. Medical Eligibility Criteria for Contraceptive Use, 5th edn. 2010. http://www.who.int/reproductivehealth/publications/family_planning/Ex-Summ-MEC-5/en/[Accessed September 25, 2015].
3.Faculty of Sexual & Reproductive Healthcare. UK Medical Eligibility Criteria for Contraceptive Use (UKMEC 2009). 2009. www.fsrh.org/pdfs/UKMEC2009.pdf.[Accessed September 22, 2014].
4.Faculty of Sexual & Reproductive Healthcare. Clinical Guidance. Contraceptive choices for women with cardiac disease. June 2014. www.fsrh.org/pdfs/CEUGuidanceContraceptiveChoicesWomenCardiac Disease.pdf.[Accessed September 22, 2014].
5.Thorne, S, Nelson-Piercy, C, MacGregor, A, et al. Pregnancy and contraception in heart disease and pulmonary arterial hypertension. J Fam Plann Reprod Health Care 2006;32:7581.
6.Presbitero, P, Somerville, J, Stone, S, Aruta, E, Spiegelhalter, D, Rabajoli, F. Pregnancy in cyanotic congenital heart disease. Circulation 1994;89:2673–6.
7.Peterson, HB, Xia, Z, Hughes, JM, Wilcox, LS, Tylor, LR, Trussell, J. The risk of pregnancy after tubal sterilisation: Findings from the U.S. Collaborative Review of Sterilisation.[CREST study] Am J Obstet Gynecol 1996;174:1161–70.
8.Royal College of Obstetricians and Gynaecologists. Male and Female Sterilisation. Evidence-based Clinical Guidelines No. 4. London: RCOG Press; 2003.
9.Farmer, M, Webb, A. Intrauterine device insertion-related complications: Can they be predicted? J Fam Plann Reprod Health Care 2003;29:227–31.
10.Sammut, MS, Paes, ML. Anaesthesia for laparoscopic cholecystectomy in a patient with Eisenmenger’s syndrome. Br J Anaesth 1997;79:810–12.
11.Snabes, MC, Poindexter, AN 3rd. Laparoscopic tubal sterilisation under local anaesthesia in women with cyanotic heart disease. Obstet Gynecol 1991;78(3 Pt 1):437–40.
12.Duffy, S, Marsh, F, Rogerson, L, Hudson, et al. Female sterilisation: A cohort controlled comparative study of ESSURE versus laparoscopic sterilisation. BJOG 2005;112:1522–8.
13.Rios-Castillo, JE, Velasco, E, Arjona-Berral, JE, Monserrat Jordan, JA, Povedano-Canizares, B, Castelo-Branco, C. Efficacy of Essure hysteroscopic sterilization: 5 years follow up of 1200 women. Gynecol Endocrinol 2013;29:580–2.
14.Povedano, B, Arjona, JE, Velasco, E, Monserrat, JA, Lorente, J, Castelo-Branco, C. Complications of hysteroscopic Essure sterilization: Report on 4306 procedures performed in a single centre. BJOG 2012;119:795–9.
15.World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: Results of an international multicentre case–control study. Lancet 1995;346:1575–82.
16.World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Acute myocardial infarction and combined oral contraceptives: Results of an international multicentre case–control study. Lancet 1997;349:1202–9.
17.Lidegaard, Ø. Oral contraceptives, pregnancy and risk of cerebral thromboembolism: The influence of diabetes, hypertension, migraine and previous thrombotic disease. Br J Obstet Gynaecol 1995;102:153–9.
18.de Swiet, J. Paradoxical embolism associated with oral contraceptives: An underdiagnosed lesion? Postgrad Med J 1979;55:419–20.
19.Lechat, P, Mas, JL, Lascault, G, et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988;318:1148–52.
20.Kerut, EK, Norfleet, WT, Plotnick, GD, Giles, TD. Patent foramen ovale: A review of associated conditions and the impact of physiological size. J Am Coll Cardiol 2001;38:613–23.
21.Oelkers, W, Helmerhorst, FM, Wuttke, W, Heithecker, R. Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers. Gynecol Endocrinol 2000;14;204–13.
22.Vasilakis, C, Jick, H, del Mar Melero-Montes, M. Risk of idiopathic venous thromboembolism in users of progestogens alone. Lancet 1999;354:1610–11.
23.World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case–control study. Contraception 1998;57:315–24.
24.Heinemann, LAJ, Assman, A, DoMinh, T, Garbe, E. Oral progestogen-only contraceptives and cardiovascular risk: Results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Eur J Contracept Reprod Health Care 1999;4:6773.
25.Dingemanse, J, van Giersbergen, PL. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 2004;43:1089–115.
26.Sorensen, MB, Collins, P, Ong, PJL, et al. Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance. Circulation 2002;106:1646–51.
27.Berenson, A, Rahman, M, Wilkinson, G. Effect of injectable and oral contraceptives on serum lipids. Am Coll Obstet Gynecol 2009;114:786–94.
28.Mantha, S, Karp, R, Raghavan, V, Terrin, N, Bauer, KA, Zwicker, JI. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: A meta-analysis. BMJ 2012;345:e4944.
29.Van, Hylckama Vlieg A, Helmerhorst, FM, Rosendaal, FR. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonogestrel intrauterine device. Arterioscler Thromb Vasc Biol 2010;30:22972300.
30.Harrison-Woolrych, M, Zhou, L, Coulter, D. Insertion of intrauterine devices: A comparison of experience with Mirena and Multiload Cu 375 during post-marketing monitoring in New Zealand. N Z Med J 2003;116:U538.
31.Funk, S, Miller, MM, Mishell, DR Jr, et al. The Implanon US Study Group. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception 2005;71:319–26.
32.Farley, TNM, Rosenberg, MJ, Rowe, PJ, Chen, JH, Meirik, O. Intrauterine devices and pelvic inflammatory disease: An international perspective. Lancet 1992;339:785–8.
33.Aznar, R, Reynoso, L, Ley, E, Gamez, R, De Leon, MD. Electrocardiographic changes induced by insertion of an intrauterine device and other uterine manipulations. Fertil Steril 1976;27:92–6.
34.National Institute for Health and Clinical Excellence. Prophylaxis against infective endocarditis. 2008. www.nice.org.uk/guidance/cg64/resources/cg64-prophylaxis-against-infective-endocarditis-full-guidance2.[Accessed September 22, 2014].
35.Faculty of Sexual & Reproductive Healthcare Clinical Guidance. Emergency Contraception. August 2011, updated July 2012. www.fsrh.org/pdfs/CEUguidanceEmergencyContraception11.pdf.[Accessed September 22, 2014].
36.Task Force on Postovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet 1998;352:428–33.
37.Ellison, J, Thomson, AJ, Greer, IA. Drug points: Apparent interaction between warfarin and levonorgestrel used for emergency contraception. BMJ 2000;321:1382.
38.Fine, P, Mathe, H, Ginde, S, Cullins, V, Morfesis, J, Gainer, E. Ulipristal acetate taken 48–120 hours after intercourse for emergency contraception. Obstet Gynecol 2010;115:257–63.
39.Glasier, AF, Cameron, ST, Logan, SJS, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: A randomised non-inferiority trial and meta-analysis. Lancet 2010;375:555–62.
40.Royal College of Obstetricians and Gynaecologists. The Care of Women Requesting Induced Abortion. Evidence-based Guideline No. 7. London: RCOG; 2011. www.rcog.org.uk/globalassets/documents/guidelines/abortion-guideline_web_1.pdf.[Accessed September 22, 2014].
41.Bedard, E, Dimopoulos, K, Gatzoulis, MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur Heart J 2009;30:256–65.
42.Kiely, DG, Condliffe, R, Webster, V, et al. Improved survival in pregnancy and pulmonary hypertension using a multiprofessional approach. BJOG 2010;117:565–74.
43.Weiss, BM, Zemp, L, Seifert, B, Hess, OM. Outcome of pulmonary vascular disease in pregnancy: A systematic overview from 1978 through 1996. J Am Coll Cardiol 1998;31:1650–7.
44.Segal, ES, Valette, C, Oster, L, et al. Risk management strategies in the postmarketing period: Safety experience with the US and European bosentan surveillance programmes. Drug Saf 2005;28:971–80.
45.Lind, J, Wallenburg, HC. The Marfan syndrome and pregnancy: A retrospective study in a Dutch population. Eur J Obstet Gynecol Reprod Biol 2001;98:2835.
46.Elkayam, U, Ostrzega, E, Shotan, A, Mehra, A. Cardiovascular problems in pregnant women with the Marfan syndrome. Ann Intern Med 1995;123:117–22.
47.Weiss, BM, von Segesser, LK, Alon, E, Seifert, B, Turina, MI. Outcome of cardiovascular surgery and pregnancy: A systematic review of the period 1984–1996. Am J Obstet Gynecol 1998;179(6 Pt 1):1643–53.